ROIV
Roivant Sciences Ltd.NASDAQHealthcare$28.33+1.76%ClosedMarket Cap: $20.28B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.62
P/S
1523.35
EV/EBITDA
-18.72
DCF Value
$3.21
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.2%
Operating Margin
-9130.5%
Net Margin
-6079.9%
ROE
-18.3%
ROA
-15.5%
ROIC
-23.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $2.0M | 65.0% | $-339.2M | $-265.9M | $-0.38 | — |
| Q2 2025 | $1.6M | 92.9% | $-306.2M | $-113.5M | $-0.17 | — |
| Q1 2025 | $2.2M | 92.9% | $-284.9M | $-223.4M | $-0.33 | — |
| Q4 2024 | $7.6M | 97.3% | $-285.0M | $-206.5M | $-0.29 | — |
| FY 2024 | $29.1M | 96.9% | $-1.00B | $-172.0M | $-0.24 | — |
| Q3 2024 | $9.0M | 97.1% | $-274.4M | $169.4M | $0.23 | — |
| Q2 2024 | $4.5M | 94.8% | $-341.7M | $-230.2M | $-0.31 | — |
| Q1 2024 | $8.0M | 97.3% | $-102.2M | $95.3M | $0.12 | — |
| Q4 2023 | $9.0M | 75.1% | $-206.8M | $-151.1M | $-0.19 | — |
| FY 2023 | $32.7M | 95.1% | $4.50B | $4.35B | $5.23 | — |
| Q3 2023 | $15.6M | 98.7% | $5.13B | $5.10B | $6.03 | — |
| Q2 2023 | $3.6M | 93.9% | $-213.9M | $-304.3M | $-0.40 | — |